Dementia caregiving is among the most psychologically demanding roles a person can take on, yet evidence-based mental health support for family caregivers remains chronically underserved. Emerging immersive technology may offer a practical workaround to the attendance and adherence barriers that have long plagued traditional mindfulness programs — a question this pilot trial is designed to begin answering.
This three-arm, single-blinded pilot randomized controlled trial protocol, published in PLOS ONE, compares a VR-based mindfulness intervention against an audio-only mindfulness format and standard care-as-usual in informal dementia caregivers. The target sample is small — nine participants per arm — reflecting its feasibility orientation rather than statistical power. The VR component simulates immersive natural environments designed to minimize domestic distractions and standardize mindfulness instruction, while preserving the scheduling flexibility that home-based care demands. Primary outcomes include psychological distress, depressive symptom burden, and perceived caregiving load; secondary outcomes extend to the quality of the caregiver-recipient relationship itself.
The rationale is well-grounded. Meta-analytic evidence already documents moderate-to-large effect sizes for mindfulness-based interventions on caregiver mental health, but real-world adherence to audio or in-person formats remains persistently low. Research in non-caregiver populations has hinted that VR-based mindfulness may outperform audio-only equivalents on engagement and affective outcomes, though this dataset is thin and largely lab-based. Translating that promise into domestic caregiving settings introduces new variables: device comfort, home noise, caregiver fatigue, and interruptions from care recipients.
Critically, this is a protocol paper — no outcome data are yet reported. Its contribution is methodological: establishing the feasibility infrastructure for a question that genuinely needs answering, given that over 50 million people live with dementia globally and that figure is projected to triple by 2050. The trial's small n limits generalizability, and single-blinding introduces performance bias risk. Still, a well-designed feasibility study like this is the necessary first step before larger adequately powered trials can be justified. Incremental but directionally important.
